Loading

Alongside its senior managers, Turenne Santé acquires ABL Lyon from Institut Mérieux, creating a new entity named Active Biomarkers.

Alongside its senior managers, Turenne Santé acquires ABL Lyon from Institut Mérieux, creating a new entity named Active Biomarkers.

ABL Lyon, a subsidiary of Institut Mérieux and a benchmark laboratory in biomarker analysis, is acquired by Turenne Santé via its private equity fund Capital Santé 2. Alongside its general manager, Marc Essodaigui, and the…

Read More
AAT-AD/PD Focus Meeting 2020 - Advances in Alzheimer's and Parkinson's Therapies
  • April 2-5, 2020
  • Vienna, Austria
  • Events

AAT-AD/PD Focus Meeting 2020 - Advances in Alzheimer's and Parkinson's Therapies

The AAT-AD/PD™ Focus Meeting 2020 in Vienna will for a second year present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological…

Read More